Oncogene

Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP™ Protein Degrader

Retrieved on: 
Wednesday, August 24, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Tether, Technology, Division, Cancer, MYC, Safety, Pharmacokinetics, Weill Cornell Medical Center, Therapy, DLBCL, Protein, Oncogene, Associate, LinkedIn, BET, Principal, Chemistry, BRD4, BCL2, Oncology, Twitter, Drug resistance, Neoplasm, Weill Cornell Medicine, Hematology, Sandra, Patient, Pharmaceutical industry

RNK05047 is Ranoks first therapy based on our proprietary CHAMP technology, as well as the first BRD4 protein degrader in the pharmaceutical industry to enter clinical testing, said Weiwen Ying, Ph.D., Founder and Chief Executive Officer of Ranok.

Key Points: 
  • RNK05047 is Ranoks first therapy based on our proprietary CHAMP technology, as well as the first BRD4 protein degrader in the pharmaceutical industry to enter clinical testing, said Weiwen Ying, Ph.D., Founder and Chief Executive Officer of Ranok.
  • Ranoks proprietary Chaperone-mediated Protein Degradation/Degrader (CHAMP) platform and Chaperone-Tether Library are based on our founders extensive backgrounds researching protein homeostasis.
  • RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranoks proprietary approach to targeted protein degradation, CHAMP.
  • Ranok is a privately held biopharmaceutical company that is pioneering CHAMP, an innovative approach to targeted protein degradation for the discovery and development of novel therapeutics.

Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company

Retrieved on: 
Monday, August 1, 2022
FC, PIPE, Type, SAN, Cancer, Neoadjuvant therapy, Securities Exchange Act of 1934, Safety, Tumor microenvironment, CD4, Perception, Securities Act of 1933, Acquisition, ASCO, U.S. Securities and Exchange Commission, Annual general meeting, Biomarker, American Society of Clinical Oncology, Lincoln Park, E2F, Nivolumab, ESMO, Cancer Research Institute, Society, Oncogene, Neoplasm, GLOBE, Nasdaq, PD-1, SEC, Pancreatic cancer, Immune system, DLA Piper, CD40, FDA, Therapy, Ovarian cancer, Sarcoma, Congress, Adoption, European Society for Medical Oncology, P.C, Patient, B cell, Wilson Sonsini Goodrich & Rosati, Chemoradiotherapy, Vaccine, Bank, Pharmaceutical industry, Nature Medicine

SAN CARLOS, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the closing of its previously announced business combination with Brookline Capital Acquisition Corp. (“BCAC”), a special purpose acquisition company. Gross proceeds from this transaction totaled $19.0 million, which included funds held in BCAC’s trust account and a concurrent private placement investment in public equity (“PIPE”) financing. The combined, publicly traded company will operate under the name Apexigen, and its common stock will commence trading on the Nasdaq Capital Market on August 1, 2022, under the ticker symbol “APGN.” Apexigen’s management team will continue leading the combined company.

Key Points: 
  • Today marks an important turning point for Apexigen as we become a publicly listed biopharmaceutical company, poised to provide innovative solutions to overcome outstanding challenges in oncology, said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen.
  • We believe sotigalimab has the potential to become a backbone of combination therapy to treat patients with cancer.
  • The proceeds from the business combination and PIPE transactions do not include potential proceeds from Lincoln Parks $50.0 million committed equity line.
  • There can be no assurance that future developments affecting the combined company will be those that the parties have anticipated.

Team Led by Boundless Bio Scientific Founders Receives $25M Award to Better Understand Extrachromosomal DNA (ecDNA) Through Cancer Grand Challenges

Retrieved on: 
Thursday, June 16, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, EGFR, Cancer, Department, Therapy, University of California, San Diego, Oncogene, Chemical biology, CRUK, Boundless, National, Biology, Scripps Research, Research, Survival, Computer science and engineering, Bio, Recurrence, Growth, DNA, Jackson Laboratory, Computational biology, University, Professor, News, Stanford University, Rolling circle replication, Associate, Radiation, Cancer Research UK, NCI, Patient, Chromosome, Florine, Computer science, Genomics, National Cancer Institute, Glioblastoma, Cell division, Immunotherapy, Dietary supplement, Management, Pharmaceutical industry, Sales, Genetics

has been awarded $25 million in funding by the National Cancer Institute (NCI*) and Cancer Research UK (CRUK) through Cancer Grand Challenges to deepen the understanding of the role of ecDNA in cancer pathogenesis.

Key Points: 
  • has been awarded $25 million in funding by the National Cancer Institute (NCI*) and Cancer Research UK (CRUK) through Cancer Grand Challenges to deepen the understanding of the role of ecDNA in cancer pathogenesis.
  • We at Boundless continue to be inspired by Dr. Mischel and the eDyNAmiC scientific teams commitment to advancing the scientific understanding of ecDNA.
  • Extrachromosomal DNA (ecDNA) are circular units of nuclear DNA that are physically distinct from chromosomes and are found within cancer cells.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile

Retrieved on: 
Friday, May 27, 2022
Cancer, Oncogene, SD, Company, Death, CRC, Annual general meeting, Private Securities Litigation Reform Act, CM24, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Survival, Food, AES, U.S. Securities and Exchange Commission, Breast cancer, KRAS, Tumor microenvironment, Abstract, Patient, STAT3, CEACAM1, PD-1, Society, Marketing, American Society of Clinical Oncology, Bristol Myers Squibb, IRS, Legislation, GEJ, Patent, DLT, Intention, PDAC, SCCHN, Insulin receptor substrate, Forward-looking statement, Neck, Safety, Neoplasm, Development of the human body, ASCO, Drug resistance, Colorectal cancer, Escape Room, Head, Drug development, Phosphorylation, Nivolumab, Pancreatic cancer, SEC, Cetuximab, CEO, Annual report, GLOBE, Medical imaging, Pharmaceutical industry

REHOVOT, Israel, May 27, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcoming tumor immune evasion and drug resistance, today announced positive interim safety and efficacy data from the Phase 1 study of NT219 in adults with advanced solid tumors. Findings will be presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting as a poster presentation during the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track (Abstract #3096).

Key Points: 
  • We are very encouraged by the initial safety and efficacy signals from NT219, and the durability of response, said Michael Schickler, Ph.D., Head of Clinical & Regularly Affairs at Purple Biotech.
  • Evaluation of NT219 safety monotherapy and in combination with cetuximab continues in additional patients with advanced cancers.
  • These data demonstrate the strong potential of NT219 as a viable treatment option for patients with cancer, said Isaac Israel, CEO of Purple Biotech.
  • Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies designed to overcome tumor immune evasion and drug resistance.

eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
U.S. Securities and Exchange Commission, Oncogene, RNA transfection, Software, Stri Parva, Annual general meeting, Private Securities Litigation Reform Act, MYC, Cyclic permutation, Infection, Survival, EIF4E, STRI, KRAS, Breast cancer, Webcast, Patient, DARPA, NASDAQ, Therapy, Pharmacokinetics, Clinical trial, Society, Pfizer, COVID-19, American Society of Clinical Oncology, NSCLC, Research, Pembrolizumab, ER, Safety, EIF4A, 4F, ASCO, RNA, Receptor tyrosine kinase, Escape Room, Security (finance), Mutation, Protein, Effector, Cancer, Cyclin D, MNK, GLOBE, Pharmaceutical industry, Vaccine, KICKSTART

SAN DIEGO and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it will present interim data from its ongoing Phase 1/2 dose escalation and expansion trial of zotatifin in multiple solid tumors in an oral poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, including safety, pharmacokinetics, pharmacodynamics and responses in two expansion cohorts.

Key Points: 
  • The data to be reported at ASCO represent the first clinical profile for this novel mechanism of action to treat cancer, said Steve Worland, Ph.D., President, and Chief Executive Officer of eFFECTOR.
  • The interim data from our ongoing trial demonstrated that the recommended Phase 2 dose (RP2D) of zotatifin was well-tolerated and achieved pharmacologically active exposures as shown by reductions in target proteins in on-treatment biopsies and by two responses as of the most recent data cut-off in the expansion cohorts.
  • We look forward to sharing more in-depth data and plan to elaborate on our expanded development plans for the zotatifin program during our investor call.
  • eFFECTOR management will host a conference call with commentary from key opinion leaders to provide additional details of the interim study results and discuss upcoming milestones.

Agastiya Biotech receives FDA Orphan Drug Designation for AB001 for Pancreatic cancer and Acute Myeloid Leukemia (AML)

Retrieved on: 
Tuesday, May 3, 2022
Oncogene, Drug resistance, AML, Toxicity, Neoplasm, Pancreatic cancer, Tumor microenvironment, Patient, RAS, PI3K, Acute lymphoblastic leukemia, FDA, Health, Moonshot, Leukemia, Research, Cancer, Multimedia, Pharmaceutical industry, Vaccine, Gemcitabine

WASHINGTON, May 3, 2022 /PRNewswire/ -- Agastiya Biotech and Vopec Pharmaceuticals announce that the US FDA has granted Orphan Drug Designations for Pancreatic Cancer and AML for its novel small molecule, AB001.

Key Points: 
  • WASHINGTON, May 3, 2022 /PRNewswire/ -- Agastiya Biotech and Vopec Pharmaceuticals announce that the US FDA has granted Orphan Drug Designations for Pancreatic Cancer and AML for its novel small molecule, AB001.
  • The research offers potential proof for the drug-ability of the so far undruggable beta-catenin and clear advantages of AB001 over Gemcitabine which is the standard of care for pancreatic cancer.
  • Furthermore, AB001 exerts anti-leukemia activity in preclinical models of acute lymphoblastic leukemia, likely through inhibiting VEGFR2-mediated signaling pathways, and suggests potential benefits and clinical application of AB001 in treating Leukemia patients.
  • AB001 preclinical studies have proved that it is able to kill cancer cells without harming normal cells.

T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Differentiable function, Cancer, Therapy, Epitope, TCR, Cell death, Molecular medicine, Patient, Oncogene, KRAS, Mouse, AACR, Hlas, American Association, Neoplasm, Allele, Cancer/testis antigens, Berlin, Association, American Association for Cancer Research, Technology, Annual general meeting, GLOBE, Toxic shock syndrome toxin, HLA, CD8, Max, SAN, Maintenance, Peptide, Toxicity, Immunization, Vaccine

This is an eventful year for T-knife, filled with meaningful corporate milestones, stated Thomas M. Soloway, Chief Executive Officer of T-knife.

Key Points: 
  • This is an eventful year for T-knife, filled with meaningful corporate milestones, stated Thomas M. Soloway, Chief Executive Officer of T-knife.
  • These TCRs mediated recognition of a large panel of KRASG12V-expressing cancer cell lines, as demonstrated by cytokine responses and cytotoxicity.
  • KRAS mutations are defined as driver mutations, meaning they are responsible for both the initiation and maintenance of cancer.
  • Targeting driver mutations reduces the potential for the tumor to employ immune escape mechanisms, making the KRAS family an ideal target for TCR-T therapy.

Boundless Bio Presents Data on the Novel Discovery of the Association Between Extrachromosomal DNA (ecDNA) and Replication Stress at the American Association for Cancer Research Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Bio, Cancer, Genome, Therapy, PM, DNA, DNA repair, Oncogene, AACR, Rolling circle replication, American Association, Poster, Association, American Association for Cancer Research, Science, Patient, Medical imaging

This study demonstrates ecDNA-enabled gene amplified cancers have inherently high replication stress, thereby providing a unique point of intervention for our novel ecDNA-directed therapeutics (ecDTx).

Key Points: 
  • This study demonstrates ecDNA-enabled gene amplified cancers have inherently high replication stress, thereby providing a unique point of intervention for our novel ecDNA-directed therapeutics (ecDTx).
  • While the drivers of replication stress remain unclear, excessive replication stress leads to extensive DNA damage and cancer cell death.
  • The results demonstrate ecDNA-enabled colorectal cancer cells have intrinsically elevated levels of replication stress and are hypersensitive to replication stress inducing agents.
  • These novel findings highlight replication stress as a potential synthetic lethal approach in ecDNA amplified cancers.

CellCentric Strengthens Leadership Team

Retrieved on: 
Wednesday, April 6, 2022
Neoplasm, University, D, Lymphatic system, Board, Oncogene, AstraZeneca, Biotechnology, Research, CBP, Cancer, Knowledge, Frese, Cancer research, Cancer Research UK, HPV Prevention and Control Board, Patient, University of Manchester, Pharmaceutical industry, Medical imaging

CellCentric is developing inobrodib, an orally bioavailable drug that is transitioning into Phase II clinical trials in multiple indications.

Key Points: 
  • CellCentric is developing inobrodib, an orally bioavailable drug that is transitioning into Phase II clinical trials in multiple indications.
  • Kris most recently served as an Associate Scientist at Cancer Research UK where he co-led the Cancer Biomarker Centre Preclinical Pharmacology Team.
  • Kris Frese, Director of Cancer Biology of CellCentric said:"I am excited to join CellCentric at this stage of development.
  • CellCentric is a research driven and patient-centric clinical stage, private biotechnology company pioneering small molecule inhibition of the twin proteins, p300/CBP.

CellCentric Strengthens Leadership Team

Retrieved on: 
Wednesday, April 6, 2022
Neoplasm, University, D, Lymphatic system, Board, Oncogene, AstraZeneca, Biotechnology, Research, CBP, Cancer, Knowledge, Frese, Cancer research, Cancer Research UK, HPV Prevention and Control Board, Patient, University of Manchester, Pharmaceutical industry, Medical imaging

CellCentric is developing inobrodib, an orally bioavailable drug that is transitioning into Phase II clinical trials in multiple indications.

Key Points: 
  • CellCentric is developing inobrodib, an orally bioavailable drug that is transitioning into Phase II clinical trials in multiple indications.
  • Kris most recently served as an Associate Scientist at Cancer Research UK where he co-led the Cancer Biomarker Centre Preclinical Pharmacology Team.
  • Kris Frese, Director of Cancer Biology of CellCentric said:"I am excited to join CellCentric at this stage of development.
  • CellCentric is a research driven and patient-centric clinical stage, private biotechnology company pioneering small molecule inhibition of the twin proteins, p300/CBP.